238 related articles for article (PubMed ID: 15067340)
1. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
4. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
Pei J; Zhang C; Gokhale PC; Rahman A; Dritschilo A; Ahmad I; Kasid UN
Anticancer Drugs; 2004 Mar; 15(3):243-53. PubMed ID: 15014358
[TBL] [Abstract][Full Text] [Related]
5. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
7. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
8. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
9. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
10. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Song S; Wientjes MG; Walsh C; Au JL
Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
[TBL] [Abstract][Full Text] [Related]
11. [Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice].
Zhang Y; Ma Y; Lu HP; Zhou XF; Xie Y; Gao JH; Liang CS
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2073-6. PubMed ID: 19080439
[TBL] [Abstract][Full Text] [Related]
12. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
13. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
18. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
Lin YJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
[TBL] [Abstract][Full Text] [Related]
19. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
